Tango Therapeutics Inc [NASDAQ: TNGX] plunged by -$0.14 during the normal trading session on while it closed the day at $7.00.
Tango Therapeutics Inc stock has also gained 6.87% of its value over the past 7 days. However, TNGX stock has declined by -24.49% in the 3 months of the year. Over the past six months meanwhile, it has lost -5.02% and lost -29.29% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for TNGX stock reached $749.98 million, with 102.20 million shares outstanding and 57.71 million shares in the current float. Compared to the average trading volume of 912.93K shares, TNGX reached a trading volume of 3274184 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Tango Therapeutics Inc [TNGX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNGX shares is $16.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNGX stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Tango Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 17, 2024. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on April 04, 2024, representing the official price target for Tango Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Piper Sandler analysts kept a Overweight rating on TNGX stock.
The Average True Range (ATR) for Tango Therapeutics Inc is set at 0.50, with the Price to Sales ratio for TNGX stock in the period of the last 12 months amounting to 17.64. The Price to Book ratio for the last quarter was 3.03, with the Price to Cash per share for the same quarter was set at 3.01.
TNGX stock trade performance evaluation
Tango Therapeutics Inc [TNGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.87. With this latest performance, TNGX shares dropped by -15.46% in over the last four-week period, additionally sinking by -5.02% over the last 6 months – not to mention a drop of -2.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNGX stock in for the last two-week period is set at 38.89, with the RSI for the last a single of trading hit 41.16, and the three-weeks RSI is set at 39.82 for Tango Therapeutics Inc [TNGX]. The present Moving Average for the last 50 days of trading for this stock 8.95, while it was recorded at 6.95 for the last single week of trading, and 9.16 for the last 200 days.
Tango Therapeutics Inc [TNGX]: An insightful look at the core fundamentals
Tango Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.49 and a Current Ratio set at 7.49.
Earnings per share (EPS) analysis for Tango Therapeutics Inc [TNGX] stock
With the latest financial reports released by the company, Tango Therapeutics Inc posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.34/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.11. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNGX.
Tango Therapeutics Inc [TNGX]: Institutional Ownership
There are presently around $90.41%, or 103.77%% of TNGX stock, in the hands of institutional investors. The top three institutional holders of TNGX stocks are: TRV GP IV, LLC with ownership of 19.2 million shares, which is approximately 17.751%. ECOR1 CAPITAL, LLC, holding 13.33 million shares of the stock with an approximate value of $$114.38 million in TNGX stocks shares; and ECOR1 CAPITAL, LLC, currently with $$80.73 million in TNGX stock with ownership which is approximately 8.6983%.
